Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells

International Journal of Cancer

Volumn 99, Issue 3, 2002, Pages 386-395

  Hoskin, David W ^a,b   Butler, Jared J ^a   Drapeau, Dennis ^a   Haeryfar, S M Mansour ^a   Blay, Jonathan ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

A3 receptor; Adenosine; Cytokines; Cytotoxicity; T lymphocytes

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 3,7 DIMETHYL 1 PROPARGYLXANTHINE; ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE DEAMINASE; COFORMYCIN; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; MESSENGER RNA; MONOCLONAL ANTIBODY CD3; N6 [2 (4 AMINOPHENYL)ETHYLADENOSINE]; N6 BENZYL 5' N ETHYLCARBOXAMIDOADENOSINE; PERFORIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; 3,7-DIMETHYL-1-PROPARGYLXANTHINE; ADENOSINE RECEPTOR; APOPTOSIS REGULATORY PROTEIN; CD3 ANTIGEN; CHROMIUM; DRUG DERIVATIVE; MEMBRANE PROTEIN; TETRAZOLIUM; THEOBROMINE; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; THYMIDINE; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; FEMALE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; KILLER CELL; LYMPHOCYTE; METABOLISM; MITOCHONDRION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADENOSINE; ADENOSINE DEAMINASE; ANIMALS; ANTIGENS, CD3; APOPTOSIS REGULATORY PROTEINS; BRAIN; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; CHROMIUM RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MITOCHONDRIA; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TETRAZOLIUM SALTS; THEOBROMINE; THIAZOLES; THYMIDINE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037140549     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10325     Document Type: Article

References (55)

1. Adoptive cellular therapy of malignancy
2. T cell recognition of human tumors: Implications for molecular immunotherapy of cancer
3. In vivo administration of anti-CD3 prevents malignant progressor tumor growth
4. Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies
5. Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody
6. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-LD experimental hepatic metastases in C57BL/6 mice
7. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy
8. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice
9. Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: Optimal conditions for the proliferation and induction of non-MHC-restricted cytotoxicity
10. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2
11. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody alone with interleukin-2 in patients with cancer
12. Tumor-infiltrating lymphocytes: Their phenotype, functions and clinical use
13. Tumor-induced immune dysfunction
14. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+T cells
15. Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction
16. Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro
17. Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours
18. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine
19. Cardiovascular purinoreceptors
20. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release
21. Blood flow, oxygen and nutrient supply and metabolic environment of human tumors: A review
22. 2 cell-surface adenosine receptor
23. 3 receptor
24. Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells
25. 2A purinergic receptor-mediated signaling in murine T cells
26. 10 thymocytes in vivo
27. A rapid method for the isolation of functional thymus-derived murine lymphocytes
28. Anti-CD3- activated killer T cells: Interferon-γ and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity
29. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow
30. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
31. The JAM test. A simple assay for DNA fragmentation and cell death
32. Measurement by quantitative PCR of changes in HRPT, PGK-1, PGK-2, APRT, Mtase and Zyf gene transcripts during mouse spermatogenesis
33. Expression of ectoadenosine deaminase and CD29 in human T cells triggered by the TCR-CD3 complex
34. Expression and utilization of chymotrypsinlike but not trypsin-like serine protease enzymes by nonspecific T killer cells activated by anti-CD3 monoclonal antibody
35. IL-2 and IFN-γ are two necessary lymphokines in the development of cytotoxic T cell
36. Association of serine protease with the rise of intracellular calcium in cytotoxic T lymphocytes
37. Nomenclature and classification of purinoreceptors
38. Microdialysis of intercellular adenosine concentration in subcutaneous tissue of humans
39. Induction of perforin and serine esterases in a murine cytotoxic T lymphocyte clone
40. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion
41. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells
42. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
43. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by tyrosine kinase inhibitors and cyclosporin A
44. Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A and inhibitors of phosphatidylinositol 3-kinase, protein kinase C and protein tyrosine kinases: Evidence for TRAIL induction via the T cell receptor signaling pathway
45. Adenosine receptors of human leukocytes - II. Characterization of an inhibitory P-site
46. "P"-site-mediated inhibition of adenylyl cyclase and its physiological implications
47. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells
48. Adenosine A3 receptor stimulation inhibits migration of human eosinophils
49. Inhibition of TNF-alpha expression by adenosine: Role of A3 adenosine receptors
50. 3 receptors decreases interleukin-12 and interferongamma production and prevents lethality in endotoxemic mice
51. 3 receptors
52. Inhibition of CTL induction by rapamycin. IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity
53. 3 adenosine receptor affects cell cycle progression and cell growth
54. 3 receptor
55. Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor